AR005613A1 - Empleo de los derivados de la tetrahidroisoquinolina - Google Patents

Empleo de los derivados de la tetrahidroisoquinolina

Info

Publication number
AR005613A1
AR005613A1 ARP970100377A ARP970100377A AR005613A1 AR 005613 A1 AR005613 A1 AR 005613A1 AR P970100377 A ARP970100377 A AR P970100377A AR P970100377 A ARP970100377 A AR P970100377A AR 005613 A1 AR005613 A1 AR 005613A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydrogen
derivatives
tetrahydroisokinoline
employment
Prior art date
Application number
ARP970100377A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR005613A1 publication Critical patent/AR005613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Se refiere al empleo de los derivados de la tetrahidrosoquinolina de fórmula general (I), en donde: A es arilo; R1 es hidrógeno, hidroxilo, alquiloinferior, alcoxilo inferior, R-CO-o R-COO-, en donde R es alquilo inferior; R2 es hidrógeno,alquilo inferior o cicloalquilo; R3-R7 son hidrógeno, alquiloinferior, alcoxilo inferior, hidroxilo o R3 y R4 tomados conjuntamente son -(CH2)n- o R6 y R7 tomados conjuntamente son -OCH2O- y n es 3 o 4; así comotambién las sales farmacéuticamente aceptables para la elaboración de medicamentos para el control o tratamiento de enfermedades que representanindicaciones terapéuticas para los bloqueadores específicos del subtipo de receptores NMDA.
ARP970100377A 1996-02-03 1997-01-30 Empleo de los derivados de la tetrahidroisoquinolina AR005613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96101553 1996-02-03

Publications (1)

Publication Number Publication Date
AR005613A1 true AR005613A1 (es) 1999-06-23

Family

ID=8222462

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100377A AR005613A1 (es) 1996-02-03 1997-01-30 Empleo de los derivados de la tetrahidroisoquinolina

Country Status (29)

Country Link
US (2) US5952344A (es)
JP (1) JP3217290B2 (es)
KR (1) KR100229298B1 (es)
CN (1) CN1167762A (es)
AR (1) AR005613A1 (es)
AU (1) AU723586B2 (es)
BR (1) BR9700816A (es)
CA (1) CA2196392A1 (es)
CO (1) CO4761069A1 (es)
CZ (1) CZ29497A3 (es)
DE (1) DE19703985A1 (es)
ES (1) ES2124672B1 (es)
FR (1) FR2744447B1 (es)
GB (1) GB2309642A (es)
HR (1) HRP970060A2 (es)
HU (1) HUP9700273A1 (es)
ID (1) ID15866A (es)
IL (1) IL120100A (es)
IT (1) IT1289621B1 (es)
MA (1) MA24078A1 (es)
NO (1) NO970431L (es)
NZ (1) NZ314130A (es)
PE (1) PE35698A1 (es)
PL (1) PL318256A1 (es)
SG (1) SG55273A1 (es)
TR (1) TR199700071A2 (es)
TW (1) TW427978B (es)
YU (1) YU3997A (es)
ZA (1) ZA97672B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
CN101815518B (zh) * 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂
JP2012158527A (ja) * 2011-01-31 2012-08-23 Mitsubishi Gas Chemical Co Inc うつ予防

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067203A (en) * 1962-12-04 Tetrahybroisqquinoline derivatives
US3217007A (en) * 1965-11-09 Halo- and nitro-substituted phenethyl-z- methyl tetrahydroisoquinolsnes
NL286505A (es) * 1961-12-15
US3243438A (en) * 1962-02-23 1966-03-29 Hoffmann La Roche Octahydro phenanthridine compounds
CH418336A (de) * 1962-02-23 1966-08-15 Hoffmann La Roche Verfahren zur Herstellung von Octahydrophenanthridinverbindungen
US3480714A (en) * 1966-02-07 1969-11-25 Ciba Geigy Corp N-substituted isoquinolines as antiprotozoal agents
US3361767A (en) * 1966-04-04 1968-01-02 American Home Prod 10, 5(epoxymethano)-10, 11-dihydro-5h-dibenzo[a, d]cyclohepten-13-one and derivatives
GB1386076A (en) * 1971-06-03 1975-03-05 Wyeth John & Brother Ltd Isoquinoline derivatives
US3803151A (en) * 1972-08-23 1974-04-09 Bristol Myers Co Synthesis for the preparation of 3-hydroxy-n-alkylisomorphinans
JPS5291868A (en) * 1976-01-26 1977-08-02 Takeda Chem Ind Ltd Indenopyridine derivatives
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
DE3664768D1 (en) * 1985-12-13 1989-09-07 Lafon Labor 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives, preparation process and medicinal use
EP0330360B1 (en) * 1988-02-19 1993-12-01 SmithKline Beecham Farmaceutici S.p.A. 1,2,3,4-Tetrahydroisoquinolines, processes for their preparation, and their use as kappa-receptor agonists
US5011834A (en) * 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
DE69132141T2 (de) * 1990-05-10 2000-09-21 Pfizer Inc., New York Neuroprotective indolone und verwandte derivate
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JPH0741481A (ja) * 1993-05-21 1995-02-10 Hokuriku Seiyaku Co Ltd 両性型三環系化合物
US5389638A (en) * 1993-09-10 1995-02-14 Abbott Laboratories Tetrahydroisoquinolines as alpha-2 antagonists and biogenic amine uptake inhibitors
US5439915A (en) * 1994-10-20 1995-08-08 American Home Products Corporation Pyrido[3,4-B]indole carboxamide derivatives as serotonergic agents
US5605906A (en) * 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof

Also Published As

Publication number Publication date
HU9700273D0 (en) 1997-03-28
TW427978B (en) 2001-04-01
AU1233597A (en) 1997-08-07
CN1167762A (zh) 1997-12-17
CA2196392A1 (en) 1997-08-04
BR9700816A (pt) 1998-07-07
MA24078A1 (fr) 1997-10-01
CO4761069A1 (es) 1999-04-27
JP3217290B2 (ja) 2001-10-09
DE19703985A1 (de) 1997-10-30
ES2124672A1 (es) 1999-02-01
YU3997A (sh) 1999-09-27
FR2744447A1 (fr) 1997-08-08
TR199700071A2 (tr) 1997-08-21
ZA97672B (en) 1997-08-04
NO970431L (no) 1997-08-04
HRP970060A2 (en) 1998-04-30
AU723586B2 (en) 2000-08-31
US6071929A (en) 2000-06-06
ITMI970153A1 (it) 1998-07-28
HUP9700273A1 (hu) 1999-08-30
KR100229298B1 (ko) 1999-11-01
JPH09221474A (ja) 1997-08-26
KR970061871A (ko) 1997-09-12
US5952344A (en) 1999-09-14
NZ314130A (en) 1998-04-27
PE35698A1 (es) 1998-07-16
GB2309642A (en) 1997-08-06
ES2124672B1 (es) 1999-11-16
IT1289621B1 (it) 1998-10-15
IL120100A (en) 2001-01-28
CZ29497A3 (en) 1997-08-13
PL318256A1 (en) 1997-08-04
FR2744447B1 (fr) 2000-09-29
GB9702049D0 (en) 1997-03-19
NO970431D0 (no) 1997-01-31
ID15866A (id) 1997-08-14
SG55273A1 (en) 1998-12-21
IL120100A0 (en) 1997-04-15

Similar Documents

Publication Publication Date Title
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
ES2161290T3 (es) Derivados de quinazolina.
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
UY26276A1 (es) 1,2,4,5- tetrahidro-benzo (d) azepinas ley 17164
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
ES2166379T3 (es) 2-aminotetralinas sustituidas.
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
SV1999000252A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer ref.pc10113abcz
AR031680A1 (es) Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
AR020590A1 (es) 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
PA8463501A1 (es) Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp)
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
UY26782A1 (es) Derivados del benzotiazol
ES2171109B2 (es) Derivados de 4-fenil-piridina.
KR960007545A (ko) 합성 흥분성 아미노산
ES2093753T3 (es) Derivados de estireno.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
ES2058449T3 (es) Nuevas piperazinilalquil-3(2h)-piridazinonas, procedimiento para su obtencion y su empleo como agentes reductores de la presion sanguinea.
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
AR005613A1 (es) Empleo de los derivados de la tetrahidroisoquinolina
AR007369A1 (es) El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados
AR005054A1 (es) Utilizacion de derivados triciclicos de 1,4-dihidro-1,4-dioxo-1h-naftaleno y sus sales, nuevos compuestos obtenidos, su aplicacion terapeutica y productosintermediarios